Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib plus platinum-pemetrexed chemotherapy versus chemotherapy alone in first-line EGFR exon 20 insertion non-squamous NSCLC
MOH_2023-12-05_013092Phase 3Recruiting
- Sponsor
- Taiho Oncology
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Taiho Oncology. Started Nov 2023; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-12-05_013092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-12-05_013092.